FEATURE
Momelotinib: Explore MOMGEMFIN as largest real world data
Shaping the future of myelofibrosis care: The role of momelotinib in addressing anemia, spleen and symptom burden in once-daily oral regimen
Myelofibrosis (MF) is a hematologic disorder characterized by splenomegaly, constitutional symptoms, ineffective hematopoiesis, and an increased risk of leukemic transformation.
Updates on the ERNEST demonstrate the survival effects of ruxolitinib on MF patients
